DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Information Disclosure Statement
The information disclosure statement (IDS) filed on 06/12/2026 has been considered here.
Status of Claims
The arguments filed 08/20/2026 are acknowledged and have been fully considered. Claims 1-8, 12-13, and 15-20 are currently pending. Claim 1 is amended; claims 9-11 and 14 are cancelled; no claims are withdrawn; no claims are new.
Claims 1-8, 12-13, and 15-20 are examined on the merits herein.
Objections/Rejections Withdrawn
Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied, and constitute the complete set presently being applied to the instant application.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claim 8 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 1 recites that the hydroxamic acid or hydroxamic acid derivative is piroctone olamine, however claim 8, which is dependent on claim 1 recites the limitation wherein the hydroxamic acid or hydroxamic acid derivative is selected from a group of compounds, including piroctone olamine. It is not clear how the hydroxamic acid or hydroxamic acid derivative can be piroctone olamine and another compound from the list of claim 8. As such, one with ordinary skill in the art would not be able to understand the metes and bounds of the claim as written. For purposes of search and consideration, the claim is understood to read “wherein the hydroxamic acid or hydroxamic acid is piroctone olamine.”
The following is a quotation of 35 U.S.C. 112(d):
(d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph:
Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
Claim 8 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. In light of the interpretation of claim 8 above, claim 8 fails to further limit the subject matter of the claim upon which it depends. Claim 1 recites “hydroxamic acid and hydroxamic acid derivative is piroctone olamine”, while claim 8 that depends on claim 1 broadens the scope by reciting more hypoxemic acid and hydroxamic acid derivatives selected from the group consisting of piroctone, caprylhydroxamic acid, benzohydroxamic acid, piroctone olamine and combinations thereof. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claims 1-8, 12-13, and 15-20 are rejected under 35 U.S.C. 103 as being unpatentable over Cochran et al. (US 2019/0105246; of record) in view of Chu et al. (WO 2021/144326; of record) and evidenced by Geary et al. (WO 2003/105793).
Claim 1 is drawn to a cleansing composition comprising:
from about 3 wt% to about 35 wt% of an anionic surfactant (more specifically sodium salts of isethionates and sodium salts of sulfosuccinates (claim 2));
from about 5 wt% to about 15% of an amphoteric surfactant (more specifically betaines (claim 18));
from about 0.01 wt% to about 2 wt% of a cationic polymer (more specifically Polyquaternium 10 and Polyquaternium 6 (claims 3-5));
from about 0 wt% to about 1.0 wt% of an inorganic salt (more specifically sodium chloride (claim 7) and from about 0 wt% to about 0.2 wt% (claims 15-17));
from about 0.01% to about 10% of piroctone olamine;
an aqueous carrier,
wherein the composition is substantially free of sulfate-based surfactant, wherein the composition has an initial viscosity greater than about 3000 cP and wherein the pH is greater than about 5.5 and less than 6.5 (claim 1), more specifically from about 3,000 cP to about 12,000 cP (claim 12).
Cochran et al. teach “personal cleansing compositions having an anionic surfactant, cationic deposition polymer, a level of inorganic salt of from about 0 to about 1 wt %, and an aqueous carrier. The composition is substantially free of sulfate containing surfactants. The composition can further comprise amphoteric surfactants” (Abstract). Cochran et al. further teach in Example 7 (Table 1 on pgs. 15-16) a cleansing composition comprising:
10% disodium laureth sulfosuccinate and 5% sodium cocoyl isethionate;
10% lauramidopropyl betaine;
0.35% Polyquaternium 10 and 0.2% Polyquaternium 6;
0.12% sodium chloride;
–
water,
wherein the composition is substantially free of sulfate-based surfactant, has a viscosity of 8500 cP, and a pH of 6.0. All percentages taught by Cochran et al. are by weight based on the total weight of the composition (Par. [0014]).
As such, Cochran et al. teach a cleansing composition comprising: from about 3 wt% to about 35 wt% of an anionic surfactant (disodium laureth sulfosuccinate and sodium cocoyl isethionate); from about 5 wt% to about 15% of an amphoteric surfactant (lauramidopropyl betaine); from about 0.01 wt% to about 2 wt% of a cationic polymer (Polyquaternium 10 and Polyquaternium 6); from about 0 wt% to about 1.0 wt% of an inorganic salt (sodium chloride); and an aqueous carrier (water), and wherein the composition is substantially free of sulfate-based surfactant, and has a viscosity from about 3,000 cP to about 12,000 cP, and a pH of greater than about 5.5 and less than 6.5.
The composition of Cochran et al. differs from the instantly claimed invention in the following way:
the composition of Cochran et al. does not comprise piroctone olamine.
Yet, as to 1: Chu et al. teach related cleaning compositions (Pg. 1 lines 11-13). Chu et al. further teach “[d]andruff is an issue that affects many people globally. The condition is manifested by the shedding of clumps of dead skin cells from the scalp. These are white and readily visible therefore they present an aesthetically displeasing appearance. A factor that contributes to dandruff is certain members of the Malassezia yeasts. To combat them, various antidandruff compositions such as shampoos are available. Usually, such shampoos contain surfactants and one or more antidandruff agent. Typical antidandruff agents are metal pyrithione e.g., zinc pyrithione (ZPTO), octopirox (piroctone olamine), azole antimicrobials (e.g., climbazole), selenium sulfide and combinations thereof” (Pg. 1 lines 15-23).
Chu et al. teach “it is preferred that the antimicrobial active according to the present invention is at least one of piroctone, caprylhydroxamic acid, benzohydroxamic acid, or piroctone olamine. It is more preferred that the antimicrobial active according to present invention is at least one of caprylhydroxamic acid or piroctone olamine. It is most preferred that the antimicrobial active is piroctone olamine” (Pg. 6 lines 5-9). Chu et al. further teach compositions comprising an antimicrobial active of hydroxamic acids or hydroxamic acid derivatives preferably comprising 0.01 to 10 wt% of said antimicrobial active (Pg. 7 lines 15-18).
And as taught by Cochran et al., “suitable optional components which can be included in a cleansing composition can include… anti-dandruff agents” (Par. [0128]). Cochran et al. further teach “the compositions can also include antimicrobial agents which are useful as cosmetic biocides and antidandruff agents including: water soluble components such as piroctone olamine” (Par. [0160]).
Therefore, it would have been prima facie obvious to a person having ordinary skill in the art before the effective filing date of the claimed invention to have modified the composition of Cochran et al. to include 0.01 to 10 wt% of piroctone olamine as taught by Chu et al. One would have been motivated to do so to modify the composition of Cochran et al. to target the well-known and widespread condition of dandruff and access a new market for the product, with a reasonable expectation of success. Further in regards to the claim limitation that the composition exhibits a % increase in viscosity after 1 week at 65°C of less than about 35%, it is pointed out that as the prior art renders obvious the instant composition, a person of ordinary skill in the art would reasonably expect the same composition to have the same properties as instantly claimed. As such the % increase in viscosity after 1 week at 65°C of less than about 35% would be expected to be the same as the instant composition by one with ordinary skill in the art.
Based on all of the foregoing, claims 1-5, 7-8, 12, and 14-18 are rejected as prima facie obvious.
Claim 6 is drawn to the composition of claim 1, wherein the charge density of the cationic polymer is from about 0.5 meq/g to about 1.7 meq/g.
Cochran et al. further teach the use of Poly JR-30M from Amerchol as the Polyquaternium-10 (Par. [0188]), which has a charge density of 1.25 meq/g as evidenced by Geary et al. (number 5 on Pg. 4).
As such, claim 6 is also rejected as prima facie obvious.
Claim 13 is drawn to the composition of claim 1, wherein a ratio of the anionic surfactant to amphoteric surfactant is from about 0.4:1 to about 1.25:1.
The composition of Cochran et al. further teach “the surfactant system can have a weight ratio of anionic surfactant to amphoteric surfactant from about 1:5 to about 10:1” (Par. [0045]), overlapping with the instantly claimed range.
As such, claim 13 is also rejected as prima facie obvious.
Claim 19 is drawn to the composition of claim 1, wherein the composition consists of 9 or fewer ingredients.
Cochran et al. further teaches that ingredients in addition to the anionic surfactant, amphoteric surfactant, cationic polymer, inorganic salt, and aqueous carrier are optional components (Par. [0127-0128]). Inclusion of piroctone olamine as taught by Chu et al. into the composition yields a composition of only 6 ingredients.
As such, claim 19 is also rejected as prima facie obvious.
Claim 20 is drawn to the composition of claim 1, wherein the composition lacks in situ coacervate, as determined by the Microscopy Method to Determine Lack of In Situ Coacervate.
Cochran et al. further teach Example 1 has no coacervate present (Table 1 on pg. 16). The method used to determine the lack of coacervate in the composition does not further impose any structural limitations to the composition and as such, bears no patentable weight.
As such, claim 20 is also rejected as prima facie obvious.
Response to Arguments
Applicant's arguments filed 08/20/2026 have been fully considered but they are not persuasive in view of the modified grounds of rejection as necessitated by amendment.
Applicant traverses the rejection of claims 1-9, 11-13, and 15-20 (now amended to claims 1-8, 12-13, and 15-20) under 35 U.S.C. as being unpatentable over Cochran et al. (US 2019/0105246) in view of Chu et al. (WO 2021/144326).
In regards to applicant’s arguments of unexpected results, applicant is reminded that whether the unexpected results are the result of unexpectedly improved results or a property not taught by the prior art, the "objective evidence of nonobviousness must be commensurate in scope with the claims which the evidence is offered to support." In other words, the showing of unexpected results must be reviewed to see if the results occur over the entire claimed range. In re Clemens, 622 F.2d 1029, 1036, 206 USPQ 289, 296 (CCPA 1980).
In the instant case, applicant presents data from example 7 to show that the claimed invention has a % increase of less than about 35% in viscosity. While it is appreciated that the claim has been amended to be more in line with the data presented, it is still not enough to establish unexpected results for the ranges of compounds taught in the claim. For example, the data is only for 0.5% by weight of piroctone olamine however the claim limitation is from 0.01% to about 10% of the composition. The data is not able to show that the unexpected results would be present in all the amounts of piroctone olamine as instantly claimed. This is an important point that needs clarification as the data shows (as discussed in the previous office action) that there is overlap between the properties of the instantly claimed composition and the comparative examples. As such, the data presented is still not commensurate in scope with the data and is not enough to establish unexpected results. The issue with the broad ranges is also present for the other compounds in claim 1. There is also the issue that the data is shown with specific compounds only. For example, the claim generally teaches an anionic surfactant but the data is not enough to establish that the unexpected results would be present with any and all anionic surfactants. As such, the argument of unexpected results is not sufficient to rebut the prima facie case of obviousness. Further applicant argues that the pH and inorganic salt concentration play a role in the surfactant hydrolysis, however again, the examples pointed to by applicant show that it is possible to achieve the viscosity as claimed without the use of piroctone olamine and the prior art also supports this with example 7, as the inorganic salt concentration and pH are within the claimed ranges (see Cochran, Table 1, example 7).
Further while acknowledging that the data presented does show a difference when piroctone olamine is used (as expected for a composition to be affected by the addition of a compound), it is not clear how this is an unexpected result for the whole range. Applicant argues against this point by saying that the difference is not an expected effect of adding a compound but a qualitatively superior and unexpected stabilization of viscosity, but due the reasons discussed above, mainly that the data is not commensurate in scope with the claims, the alleged unexpected benefits cannot be acknowledged for the whole scope of the claims and the argument is not persuasive in establishing unexpected results in order to overcome the rejections of record.
As such, the rejections of record are maintained over the claims as obvious.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 1-8, 12-13, and 15-20 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1-17 and 19-20 of copending Application No. 17/961,148 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other.
Claim 1 of copending application ‘148 is drawn to a clear cleansing composition comprising: from about 3 wt% to about 35 wt% of an anionic surfactant; from about 5 wt% to about 15% of an amphoteric surfactant; from about 0.01 wt% to about 2 wt% of a cationic polymer; from about 0 wt% to about 1.0 wt% of inorganic salts; from about 0.01% to about 10% of a hydroxamic acid or hydroxamic acid derivative consisting of piroctone olamine; an aqueous carrier, wherein the composition is substantially free of sulfate based surfactant and wherein the composition has a %T value of greater than about 70. Claim 10 of copending application ‘148 is drawn to the composition of claim 1 wherein the composition has a viscosity greater than about 2000 cP. Claims 1 and 10 of copending application ‘148 anticipate instant claim 1. Claims 2-9 and 11 of copending application ‘148 overlap with instant claims 2-9 and 11-12. Claims 12-17 of copending application ‘148 are identical in scope to instant claims 13 and 15-18. Claims 19-20 of copending application ‘148 overlap with instant claims 19-20.
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Claims 1-8, 12-13, and 15-20 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-6 and 8-18 of copending Application No. 19049671 in view of Chu et al. (WO 2021/144326; of record).
19049671 claims are drawn to a shampoo composition comprising a stable shampoo composition comprising: A. a surfactant system comprising: i. about 3% to about 35% of an anionic surfactant; ii. about 5% to about 15% of an amphoteric surfactant; wherein the surfactant system is substantially free of sulphated surfactants; B. about 0.01% to about 2% of a cationic polymer; C. about 0.15% to about 1.5% of a thickener comprising sclerotium gum; wherein the composition has a viscosity of greater than 2500 cP and a pH of greater than 5.5 (see claim 1). Further claim 2 recites the limitation of the composition comprising less than about 1% of an inorganic salt (see claim 2). The list of inorganic salts in claim 3 is identical to the list in instant claim 7.
In regards to claims 4-5 of 19049671 recite the viscosity and pH overlaps with the ranges in the instant claims.
In regards to claims 8-9 and 17, there is no mention of alkyl polyglucoside, fatty esters, or silicones in the instant claims, thus are free of them.
In regards to claims 12-14, the lists of components are identical to the instant claims.
In regards to claims 15-16, the composition teaches the use of piroctone olamine in the composition.
In regards to claim 18, the limitation is identical to instant claim 19.
19049671 is silent on the amount of hydroxamic acid or hydroxamic acid derivative (i.e., piroctone olamine).
The teachings of Chu et al. have been described supra.
In regards to claims 1-8, 12-13, and 15-20, it would have been prima facie obvious to a person of ordinary skill in the art, before the effective filing date of the claimed invention, to combine the teachings of 19049671 and Chu et al. to formulate a composition as instantly claimed as both references
teach compositions comprising similar compounds. Further, 19049671 teaches that the composition comprises compounds piroctone olamine but is silent on the amounts used and Chu et al. gives one with ordinary skill in the art an idea of what amounts these compounds are used in a similar composition. "It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose .... [T]he idea of combining them flows logically from their having been individually taught in the prior art." In re Kerkhoven, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980). One with ordinary skill in the art would be motivated to combine the composition of 19049671 with the amounts of Chu et al. according to the known method of making a topical composition (see Chu et al, Examples, method 1) to yield predictable results with a reasonable expectation of success. One with ordinary skill in the art would be motivated to combine prior art elements according to known methods to yield predictable results.
In regards to claims 6, 10, and 11 of the 19049671, specifically to the limitations of “wherein the stable shampoo composition has a yield stress of greater than…Test Method”, a %T at 600nm of greater than 70%, and wherein the shampoo lacks an in situ coacervate, the combination of teachings of 19049671 and Chu renders it obvious to arrive at the composition as instantly claimed. As the combined teachings of the prior art arrives at the composition as claimed, the properties applicant discloses and/or claims would necessarily follow absent evidence to the contrary.
This is a provisional nonstatutory double patenting rejection.
Claims 1-8, 12-13, and 15-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-13 of U.S. Patent No. 12708594 in view of Cochran et al. (US 2019/0105246; of record) and Chu et al. (WO 2021/144326; of record).
12708594 claims are drawn to a cleansing composition comprising: a) about 3 wt % to about 35 wt % of an acyl taurate anionic surfactant; about 3 wt % to about 15% of an amphoteric surfactant; about 0.01 wt % to about 2 wt % cationic polymer having a weight average molecular weight of 300,000 g/mol to about 3,000,000 g/mol; about 0 wt % to about 1.0 wt % of inorganic salts; and an aqueous carrier, wherein the composition is substantially free of sulfate-based surfactant and does not form a coacervate prior to use. Dependent claims 2-3 list examples of acyl taurate anionic surfactants, all of which fall under the category of an anionic surfactant of the instant claims. Claims 4-6 and 13 list examples of cationic polymers, inorganic salts, and amphoteric surfactants that are identical to those in the instant claims. Claim 7 teaches a viscosity that overlaps with the instant claims. Claims 8-12 describe additional components and forms that the composition comprises.
12708594 is silent on the use and amount of hydroxamic acid or hydroxamic acid derivative (i.e., piroctone olamine).
The teachings of Cochran et al. and Chu et al. have been described supra.
In regards to claims 1-8, 12-13, and 15-20, it would have been prima facie obvious to a person of ordinary skill in the art, before the effective filing date of the claimed invention, to combine the teachings of 12708594 with Cochran et al. and Chu et al. to formulate a composition as instantly claimed as 18637740 and Cochran teach compositions comprising similar compounds. Further, Cochran et al. teaches that the composition comprises compounds piroctone olamine but is silent on the amounts used and Chu et al. gives one with ordinary skill in the art an idea of what amounts these compounds are used in a similar composition. "It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose .... [T]he idea of combining them flows logically from their having been individually taught in the prior art." In re Kerkhoven, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980). One with ordinary skill in the art would be motivated to combine the composition of 12708594 with the compounds and amounts of Cochran et al. and Chu et al. according to the known method of making a topical composition (see Chu et al, Examples, method 1) to yield predictable results with a reasonable expectation of success. One with ordinary skill in the art would be motivated to combine prior art elements according to known methods to yield predictable results.
Claims 1-8, 12-13, and 15-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-15 of U.S. Patent No. 11904036 in view of Cochran et al. (US 2019/0105246; of record) and Chu et al. (WO 2021/144326; of record).
11904036 claims are drawn to a cleaning composition comprising about 3 wt % to about 35 wt % of an anionic surfactant; about 5.8 wt % to about 15% of an amphoteric surfactant; about 0.01 wt % to about 2 wt % cationic polymer; about 0 wt % to about 1.0 wt % of inorganic salts; and an aqueous carrier, wherein the composition is substantially free of sulfate-based surfactant, does not form a coacervate prior to use, and has a viscosity of about 100 cP to about 15,000 cP measured at 26.6° C with a Brookfield R/S Plus Rheometer at 2 s−1. The list of anionic surfactants, cationic polymers, inorganic salts, and amphoteric surfactants, as well as the properties thereof overlap with those of the instant claims (see 11904036, claims 2-7 and 14-15). Claims 8-13 describe additional components and forms that the composition comprises.
11904036 is silent on the use and amount of hydroxamic acid or hydroxamic acid derivative (i.e., piroctone olamine).
The teachings of Cochran et al. and Chu et al. have been described supra.
In regards to claims 1-8, 12-13, and 15-20, it would have been prima facie obvious to a person of ordinary skill in the art, before the effective filing date of the claimed invention, to combine the teachings of 11904036 with Cochran et al. and Chu et al. to formulate a composition as instantly claimed as 11904036 and Cochran teach compositions comprising similar compounds. Further, Cochran et al. teaches that the composition comprises compounds piroctone olamine but is silent on the amounts used and Chu et al. gives one with ordinary skill in the art an idea of what amounts these compounds are used in a similar composition. "It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose .... [T]he idea of combining them flows logically from their having been individually taught in the prior art." In re Kerkhoven, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980). One with ordinary skill in the art would be motivated to combine the composition of 11904036 with the compounds and amounts of Cochran et al. and Chu et al. according to the known method of making a topical composition (see Chu et al, Examples, method 1) to yield predictable results with a reasonable expectation of success. One with ordinary skill in the art would be motivated to combine prior art elements according to known methods to yield predictable results.
Claims 1-8, 12-13, and 15-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-19 of U.S. Patent No. 11992540 B2 in view of Cochran et al. (US 2019/0105246; of record) and Chu et al. (WO 2021/144326; of record).
11992540 claims are drawn to a cleansing composition comprising: a) about 3 wt % to about 35 wt % of an anionic surfactant; b) about 3 wt % to about 15% of an amphoteric surfactant; c) about 0.01 wt % to about 2 wt % of a cationic polymer having a weight average molecular weight of 300,000 g/mol to about 3,000,000 g/mol; d) about 0 wt % to about 1.0 wt % of inorganic salts; and e) an aqueous carrier, wherein the composition is substantially free of sulfate-based surfactant and does not form a coacervate prior to use. The list of anionic surfactants, cationic polymers, inorganic salts, and amphoteric surfactants, as well as the properties thereof overlap with those of the instant claims (see 11992540, claims 1-6 and 13-16). Claim 7 teaches a viscosity that overlaps with the instant claims as well. Claims 8-12 describe additional components and forms that the composition comprises and claims 17-19 recite different embodiments of the composition with similar amounts as the instant claims.
11992540 is silent on the use and amount of hydroxamic acid or hydroxamic acid derivative (i.e., piroctone olamine).
The teachings of Cochran et al. and Chu et al. have been described supra.
In regards to claims 1-8, 12-13, and 15-20, it would have been prima facie obvious to a person of ordinary skill in the art, before the effective filing date of the claimed invention, to combine the teachings of 11992540 with Cochran et al. and Chu et al. to formulate a composition as instantly claimed as 11992540 and Cochran teach compositions comprising similar compounds. Further, Cochran et al. teaches that the composition comprises compounds piroctone olamine but is silent on the amounts used and Chu et al. gives one with ordinary skill in the art an idea of what amounts these compounds are used in a similar composition. "It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose .... [T]he idea of combining them flows logically from their having been individually taught in the prior art." In re Kerkhoven, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980). One with ordinary skill in the art would be motivated to combine the composition of 11992540 with the compounds and amounts of Cochran et al. and Chu et al. according to the known method of making a topical composition (see Chu et al, Examples, method 1) to yield predictable results with a reasonable expectation of success. One with ordinary skill in the art would be motivated to combine prior art elements according to known methods to yield predictable results.
Response to Arguments
Applicant's arguments filed 08/20/2026 have been fully considered but they are not persuasive.
In response, the examiner notes that a request to address the issue further upon an indication of allowance is not a proper response to a rejection. Rather, a request to hold a matter in abeyance may only be made in response to an OBJECTION or REQUIREMENTS AS TO FORM (see MPEP 37 CFR 1.111(b) and 714.02). As set forth above, the double patenting rejections of claims 1-8 and 12-20 are maintained.
Conclusion
No claims allowed.
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to AYAAN A ALAM whose telephone number is (571)270-1213. The examiner can normally be reached M-F 8-5 EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bethany Barham can be reached at 571-272-6175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/ISIS A GHALI/Primary Examiner, Art Unit 1611
/A.A.A./Examiner, Art Unit 1611